Krystal Biotech, Inc. KRYS
Nov 10, 2026, 1:28 PM EST
- YTD
- +23.17%
- 1 year
- +52.19%
- Market cap
- 8.99B
- Revenue (ttm)
- 470.02M
- Profit margin
- 47.91%
- EPS (ttm)
- 7.36
- Shares out
- 29.63M
- P/E ratio
- 41.24
- Forward P/E
- 32.84
- YTD return
- +23.17%
- 1-year return
- +52.19%
- Volume
- 58.66K
- Avg volume
- 281.54K
- Open
- 302.60
- Previous close
- 303.06
- Day's range
- 300.86 – 307.42
- 52-week range
- 198.02 – 382.54
- Beta
- 0.65
- Analysts
- Strong Buy
- Price target
- 388.22 (+27.8%)
- Earnings date
- Feb 16, 2027
5D -7.04 (-2.28%)
Key statistics
- Enterprise value
- 8.01B
- PEG ratio
- 0.00
- Price / sales
- 19.11
- Price / book
- 6.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 30.20%
- Free cash flow
- 221.59M
- Total cash
- 911.85M
- Total debt
- 8.59M
- Return on equity
- 17.50%
- Short % of float
- 16.21%
- 50-day average
- 332.49
- 200-day average
- 309.01
Analyst view
Consensus: strong buy
- Target (low)
- 284.00
- Target (mean)
- 388.22
- Target (high)
- 474.00
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 2.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 2.05 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 1.79 | 2.05 | +0.26 | +14.53% |
| Aug 3, 2026 | Jun 30, 2026 | 1.70 | 1.79 | +0.09 | +5.29% |
| May 4, 2026 | Mar 31, 2026 | 1.45 | 1.83 | +0.38 | +26.21% |
| Feb 17, 2026 | Dec 31, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
| Nov 3, 2025 | Sep 30, 2025 | 1.12 | 2.66 | +1.54 | +137.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 3, 2026 | TD Cowen | main | Buy | Buy |
| Nov 3, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 14, 2026 | RBC Capital | init | — | Outperform |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- krystalbio.com
News
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street Analysts 
Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412 
TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380 
RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375 
Krystal Biotech Analyst Says Stock Weakness 'Overblown' 
Krystal Biotech Q3 2026 Earnings Call Transcript 
Krystal Biotech Q3 EPS $2.05 Beats $1.77 Estimate, Sales $127.341M Beat $126.079M Estimate 
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test 
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today 
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
Your note
Sign in to keep a note on KRYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JANNEY DANIEL SPENCER | Director | Sale | Feb 26, 2026 | 0 |
| KRISHNAN KRISH S | Chief Executive Officer | Sale | Sep 3, 2026 | 1,565,250 |
| KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Sale | Sep 3, 2026 | 1,493,160 |
| ROMANO KATHRYN | Officer | Sale | Mar 1, 2026 | 22,366 |
| ROSSI DINO A | Director | Stock Gift | Aug 13, 2026 | 50,000 |
| THOMAS JOHN CHARLES MICHAEL | General Counsel | Sale | Jun 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.91% | 4,418,197 | 1.34B | Jun 29, 2026 |
| Blackrock Inc. | 14.11% | 4,181,432 | 1.27B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 9.75% | 2,888,888 | 875.51M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.31% | 1,574,905 | 477.29M | Jun 29, 2026 |
| State Street Corporation | 4.56% | 1,351,158 | 409.48M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 1,240,567 | 375.97M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.08% | 1,802,622 | 546.30M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.20% | 948,897 | 287.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 889,548 | 269.59M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.75% | 816,132 | 247.34M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.54% | 752,244 | 227.98M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 675,066 | 204.59M | Sep 29, 2026 |